[vc_row][vc_column][vc_column_text]Pulmonary hypertension (PH) is a rare but severe disease characterized by high blood pressure in the lungs. The disease affects the pulmonary arteries, which are ...

Reflecting on this year's PHA conference in Dallas, columnist Mike Naple writes that connecting with community can be the ...

Most PAH patients who completed one year in a CS1 expanded access program had stable or improved clinical measures.

A study linked elevated blood levels of uric acid, a metabolic breakdown product often associated with gout, to a higher risk ...

Blocking a signaling pathway in certain white blood cells may prevent clots from obstructing blood flow and causing CTEPH, per a new study.

Nine members of the pulmonary hypertension (PH) community have received awards for their support of the Pulmonary Hypertension Association (PHA). At the PHA 2026 International PH Conference and ...

Oxiwear‘s wearable medical device, which continuously tracks oxygen levels in people with pulmonary hypertension (PH) and other heart or lung conditions, will now be covered by Medicare and certain ...

Share this page with email Share this page on Facebook Share this page on X Share this page on Reddit Print Preferred Source on Google In a recent column, I shared something I’d been too stubborn to ...

Enrollment is complete in the Phase 2 APEX trial of TX45, Tectonic Therapeutic‘s experimental drug for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), ...

A gene called NDRG1 may help drive blood vessel remodeling seen in chronic thromboembolic pulmonary hypertension (CTEPH) by shifting smooth muscle cells toward a scar-forming state, a study found.